Literature DB >> 7768455

Eosinophils and allergy in asthma.

S Makino1, T Fukuda.   

Abstract

Eosinophils are recruited to the site of IgE-mediated allergic reaction in the airway in asthma. Major eosinophil-chemotactic factors released from mast cells are platelet activating factor and Leukotriene B4. In addition, T cells and bronchial epithelial cells produce eosinophil chemotactic cytokines. Cytokines including IL-5, IL-3, and GM-CSF, which are released mainly from CD4+ T cells and possibly Th2, activates eosinophils for migration, tissue damage, and survival. Adhesion molecules on eosinophils and constituent structures of the airway participate in the process of eosinophil migration. Among a variety of adhesion molecules, VLA-4 and VCAM-1 are unique to the interaction between eosinophils and endothelial cells. A major role of recruited eosinophils in the airway in asthma is considered to be damage to the bronchial epithelium caused by eosinophil specific granules proteins, in addition to production of lipid mediators, production of cytokines, antigen-presenting cell function, and possible induction of basement membrane thickening in the airway.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7768455     DOI: 10.2500/108854195778690110

Source DB:  PubMed          Journal:  Allergy Proc        ISSN: 1046-9354


  3 in total

1.  Serotonin 5-HT₂ receptor activation prevents allergic asthma in a mouse model.

Authors:  Felix Nau; Justin Miller; Jordy Saravia; Terry Ahlert; Bangning Yu; Kyle I Happel; Stephania A Cormier; Charles D Nichols
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-01-15       Impact factor: 5.464

2.  Interleukin-3 production by mast cells from human lung.

Authors:  T Ishizuka; Y Okayama; H Kobayashi; M Mori
Journal:  Inflammation       Date:  1999-02       Impact factor: 4.092

3.  Eosinophils in fungus-associated allergic pulmonary disease.

Authors:  Sumit Ghosh; Scott A Hoselton; Glenn P Dorsam; Jane M Schuh
Journal:  Front Pharmacol       Date:  2013-02-01       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.